398 filings
8-K
PGNX
Progenics Pharmaceuticals Inc
22 Jun 20
Lantheus Completes Merger with Progenics
7:55am
8-K
PGNX
Progenics Pharmaceuticals Inc
17 Jun 20
Submission of Matters to a Vote of Security Holders
5:16pm
8-K
PGNX
Progenics Pharmaceuticals Inc
16 Jun 20
Progenics Stockholders Approve Merger with Lantheus
5:02pm
8-K
PGNX
Progenics Pharmaceuticals Inc
11 Jun 20
Departure of Directors or Certain Officers
4:46pm
8-K
PGNX
Progenics Pharmaceuticals Inc
8 Jun 20
Other Events
4:54pm
8-K
zpeaj8gjawfl6 x0a5
28 May 20
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
4:03pm
8-K
mokhk
18 May 20
Regulation FD Disclosure
4:01pm
8-K
hq2teeww
7 May 20
Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update
8:00am
8-K
pb2eyhpyz9k q0p
14 Apr 20
Velan Capital Agrees to Support Merger of Lantheus and Progenics
5:00pm
8-K
el8vfbdc
2 Apr 20
Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger
9:02am
8-K
hp2saxc 28
1 Apr 20
Departure of Directors or Certain Officers
4:44pm
8-K
ivln2h3
16 Mar 20
Entry into a Material Definitive Agreement
6:03am
8-K
lsxg3z4
13 Mar 20
Progenics Pharmaceuticals Announces Fourth Quarter and Full-year 2019 Financial Results
8:45am
8-K
tb489j 95lf9
4 Mar 20
Departure of Directors or Certain Officers
5:04pm
8-K
zsa77vkhmvlc76k e5dj
20 Feb 20
Entry into a Material Definitive Agreement
5:01pm
8-K
lfg hywut69lk
20 Feb 20
Lantheus and Progenics Agree to Amended Transaction Terms
1:27pm
8-K
r1g32
21 Jan 20
Regulation FD Disclosure
5:27pm
8-K
lp13hzbpqm
23 Dec 19
Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyLTM in Prostate Cancer Achieved Primary Endpoint
7:32am
8-K
ujr4jqrsxuustpks
19 Dec 19
Departure of Directors or Certain Officers
4:03pm
8-K
csmyiewxua54yas ne
21 Nov 19
Departure of Directors or Certain Officers
4:12pm